Lantheus (NASDAQ:LNTH) Price Target Cut to $122.00 by Analysts at B. Riley

Lantheus (NASDAQ:LNTH) had its target price decreased by research analysts at B. Riley from $127.00 to $122.00 in a research report issued on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the medical equipment provider’s stock. B. Riley’s price target would suggest a potential upside of 23.42% from the company’s previous close.

Other equities research analysts also recently issued research reports about the stock. Truist Financial boosted their price objective on shares of Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a research report on Thursday, February 27th. The Goldman Sachs Group started coverage on Lantheus in a report on Wednesday, December 18th. They set a “buy” rating and a $143.00 target price for the company. JMP Securities reissued a “market outperform” rating and issued a $112.00 price target on shares of Lantheus in a report on Tuesday, January 14th. Finally, StockNews.com downgraded Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $129.43.

Lantheus Trading Down 4.3 %

Shares of LNTH opened at $98.85 on Friday. The firm has a market cap of $6.77 billion, a price-to-earnings ratio of 16.45 and a beta of 0.38. Lantheus has a 52 week low of $57.92 and a 52 week high of $126.89. The stock has a 50 day moving average of $92.64 and a 200-day moving average of $96.70.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). The business had revenue of $391.11 million during the quarter, compared to analyst estimates of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. On average, sell-side analysts predict that Lantheus will post 6.01 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Mary Anne Heino sold 53,107 shares of the company’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the sale, the director now owns 440,399 shares of the company’s stock, valued at $41,551,645.65. This represents a 10.76 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the transaction, the chief financial officer now owns 113,860 shares of the company’s stock, valued at $11,445,207.20. This represents a 8.07 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 64,109 shares of company stock valued at $6,110,806 in the last three months. 1.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Wilmington Savings Fund Society FSB bought a new stake in Lantheus during the third quarter worth approximately $25,000. Kestra Investment Management LLC bought a new stake in shares of Lantheus in the 4th quarter worth $27,000. Summit Securities Group LLC bought a new stake in shares of Lantheus in the 4th quarter worth $37,000. UMB Bank n.a. lifted its holdings in shares of Lantheus by 31.5% in the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock valued at $50,000 after buying an additional 134 shares during the period. Finally, Parkside Financial Bank & Trust boosted its stake in Lantheus by 49.4% during the fourth quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider’s stock valued at $76,000 after buying an additional 280 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.